Fetuin‐A, inter‐α‐trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes
Laia Reverté(Institute for Research and Technology in Food and Agriculture), Ezequiel Ruíz-Mateos(Apple (Israel)), Anna Rull(Institut de Recerca Biomèdica Catalunya Sud), Anna Martí(Institut de Recerca Biomèdica Catalunya Sud), Clara Benavent‐Bofill(Hospital Universitari Joan XXIII de Tarragona), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Joaquín Burgos, Luís F. López‐Cortés(Instituto de Salud Carlos III), María J. Buzón(Universitat Autònoma de Barcelona), Fréderic Gómez-Bertomeu, Elena Yeregui(Institut de Recerca Biomèdica Catalunya Sud), Teresa Auguet(Institut de Recerca Biomèdica Catalunya Sud), Alicia Gutiérrez‐Valencia(Consejo Superior de Investigaciones Científicas), Maria Teresa Mestre(Hospital Universitari Joan XXIII de Tarragona), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Montserrat Olona(Institut de Recerca Biomèdica Catalunya Sud), Joaquim Peraire(Instituto de Salud Carlos III), Graciano García‐Pardo(Instituto de Salud Carlos III), Carme Boqué(Hospital Universitari Joan XXIII de Tarragona)
Cited by 16
Related Papers
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
|Science Translational Medicine|2017|169
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection
|Clinical Infectious Diseases|2017|146
Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa
|Nature Communications|2019|120
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|The Lancet HIV|2021|110
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
|Clinical Infectious Diseases|2017|103